BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. APLD
3. STZ
4. CRGY
5. RMR
6. GOOG
7. SPY
8. ANGO
9. LULU
10. PEP

Go back to BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform

Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program

May 26, 2016 7:30 AM EDT

CARLSBAD, Calif., May 26, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on the IONIS-TTRRx program.  Ionis is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy.  Dr. Merrill Benson is also evaluating IONIS-TTRRx in an investigator-initiated Phase 2 open-label study in patients with TTR-related amyloid cardiomyopathy.

GSK, which has an... More